309 related articles for article (PubMed ID: 30471956)
1. Prioritization of risk groups for influenza vaccination in resource limited settings - A case study from South Africa.
McMorrow ML; Tempia S; Walaza S; Treurnicht FK; Ramkrishna W; Azziz-Baumgartner E; Madhi SA; Cohen C
Vaccine; 2019 Jan; 37(1):25-33. PubMed ID: 30471956
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of antenatal influenza vaccination among HIV-infected and HIV-uninfected pregnant women in South Africa.
Biggerstaff M; Cohen C; Reed C; Tempia S; McMorrow ML; Walaza S; Moyes J; Treurnicht FK; Cohen AL; Hutchinson P; Stoecker C; Steinberg J
Vaccine; 2019 Oct; 37(46):6874-6884. PubMed ID: 31575494
[TBL] [Abstract][Full Text] [Related]
3. Influenza disease burden among potential target risk groups for immunization in South Africa, 2013-2015.
Tempia S; Walaza S; Moyes J; McMorrow ML; Cohen AL; Edoka I; Fraser H; Treurnicht FK; Hellferscee O; Wolter N; von Gottberg A; McAnerney JM; Dawood H; Variava E; Cohen C
Vaccine; 2020 Jun; 38(27):4288-4297. PubMed ID: 32389494
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department.
Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K
JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729
[TBL] [Abstract][Full Text] [Related]
5. Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.
de Fougerolles TR; Baïssas T; Perquier G; Vitoux O; Crépey P; Bartelt-Hofer J; Bricout H; Petitjean A
BMC Public Health; 2024 May; 24(1):1222. PubMed ID: 38702667
[TBL] [Abstract][Full Text] [Related]
6. Net Costs Due to Seasonal Influenza Vaccination--United States, 2005-2009.
Carias C; Reed C; Kim IK; Foppa IM; Biggerstaff M; Meltzer MI; Finelli L; Swerdlow DL
PLoS One; 2015; 10(7):e0132922. PubMed ID: 26230271
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Effect of a National Pharmacy-Led Influenza Vaccination Voucher Program on Morbidity, Mortality, and Costs.
Singh T; Taitel M; Loy D; Smith-Ray R
J Manag Care Spec Pharm; 2020 Jan; 26(1):42-47. PubMed ID: 31880234
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children.
Luce BR; Zangwill KM; Palmer CS; Mendelman PM; Yan L; Wolff MC; Cho I; Marcy SM; Iacuzio D; Belshe RB
Pediatrics; 2001 Aug; 108(2):E24. PubMed ID: 11483834
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US.
Peasah SK; Meltzer MI; Vu M; Moulia DL; Bridges CB
PLoS One; 2019; 14(4):e0213499. PubMed ID: 31034485
[TBL] [Abstract][Full Text] [Related]
11. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.
Brydak L; Roiz J; Faivre P; Reygrobellet C
Clin Drug Investig; 2012 Feb; 32(2):73-85. PubMed ID: 22201294
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility of quadrivalent versus trivalent influenza vaccine in Brazil - comparison of outcomes from different static model types.
Van Bellinghen LA; Marijam A; Tannus Branco de Araujo G; Gomez J; Van Vlaenderen I
Braz J Infect Dis; 2018; 22(1):1-10. PubMed ID: 29352897
[TBL] [Abstract][Full Text] [Related]
13. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
14. Influenza economic burden among potential target risk groups for immunization in South Africa, 2013-2015.
Tempia S; Moyes J; Cohen AL; Walaza S; McMorrow ML; Edoka I; Fraser H; Treurnicht FK; Hellferscee O; Wolter N; von Gottberg A; McAnerney JM; Dawood H; Variava E; Cohen C
Vaccine; 2020 Oct; 38(45):7007-7014. PubMed ID: 32980198
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.
Edoka I; Kohli-Lynch C; Fraser H; Hofman K; Tempia S; McMorrow M; Ramkrishna W; Lambach P; Hutubessy R; Cohen C
Vaccine; 2021 Jan; 39(2):412-422. PubMed ID: 33272702
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
17. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ
Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545
[TBL] [Abstract][Full Text] [Related]
18. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
19. Burden of medically attended influenza infection and cases averted by vaccination - United States, 2013/14 through 2015/16 influenza seasons.
Jackson ML; Phillips CH; Benoit J; Jackson LA; Gaglani M; Murthy K; McLean HQ; Belongia EA; Malosh R; Zimmerman R; Flannery B
Vaccine; 2018 Jan; 36(4):467-472. PubMed ID: 29249545
[TBL] [Abstract][Full Text] [Related]
20. Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50-64 years old.
Raj SM; Chughtai AA; Sharma A; Tan TC; MacIntyre CR
Vaccine; 2019 Sep; 37(40):5979-5985. PubMed ID: 31473001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
